Publication: Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma
No Thumbnail Available
Open/View Files
Date
2023-03-27
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Science and Business Media LLC
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Kwok, Hui, Allyson M. Freedy, Allison P. Siegenfeld, Julia W. Morriss, Amanda L. Waterbury, Stephen M. Kissler, Brian B. Liau. "Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma." Nat Chem Biol No Volume. DOI: 10.1038/s41589-023-01299-1
Research Data
Abstract
Drug addiction, a phenomenon where cancer cells paradoxically depend on continuous drug treatment for survival, has uncovered cell signaling mechanisms and cancer co-dependencies. Here, we discover mutations that confer drug addiction to inhibitors of the transcriptional repressor Polycomb Repressive Complex 2 (PRC2) in diffuse large B-cell lymphoma (DLBCL). Drug addiction is mediated by hypermorphic mutations in the CXC domain of the catalytic subunit EZH2, which maintain H3K27me3 levels even in the presence of PRC2 inhibitors. Drug discontinuation leads to overspreading of H3K27me3, surpassing a repressive methylation ceiling compatible with lymphoma cell survival. Exploiting this vulnerability, we show that inhibition of SETD2 similarly induces H3K27me3 spreading and blocks lymphoma growth. Collectively, our findings demonstrate that constraints on chromatin landscapes can yield biphasic dependencies in epigenetic signaling in cancer cells. More broadly, we highlight how approaches to identify drug addiction mutations can be leveraged to discover cancer vulnerabilities.
Description
Other Available Sources
Keywords
Cell Biology, Molecular Biology
Terms of Use
Metadata Only